AAM Urges US Senate To Back Domestic Production
AAM Insists The Supply Chain Is Safe, But Could Be Improved
While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”
You may also be interested in...
Fresh from its $812m government contract to help prevent shortages of essential medicines and shield the US market from global competition, domestic start-up Phlow Corporation has received further financial backing.
Fresenius Kabi has announced plans for six new launches along with fresh investment in manufacturing in the US market after the firm saw a 10% drop in North American sales in the third quarter. However, the company’s business in China saw a “solid recovery” to “pre-pandemic levels.”
US start-up Phlow has been awarded federal government funding of $354m as part of a contract to manufacture essential medicines in the US amid the COVID-19 pandemic, in partnership with AMPAC Fine Chemicals and Civica Rx.